Get to know our clinical trials

Phase I/II clinical trial of BMS-986482 as monotherapy and in combination in participants with advanced solid tumors.

Imagen del Dr. Ignacio Melero Bermejo, especialista en Inmunología de la Clínica Universidad de Navarra.
Dr. Ignacio Melero Bermejo Curriculum
Codirector Immunology and Immunotherapy Department
Navarre headquarters
Cancer Center
Lung Cancer Area
Status
In recruitment
headquarters
Pamplona/Madrid

Technical Summary

  • PHASE I/II STUDY OF BMS-986482 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS.
  • Code EudraCT: 2024-516602-28
  • Protocol number: CA236-0001
  • Promoter: Bristol Myers Squibb
  • Molecule/Drug: BMS-986482
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION